modelFenfluramine
Extends from Pharmacolibrary.Drugs.ATC.A.A08AA02.
Information
| name: | Fenfluramine | |
| ATC code: | A08AA02 | route: | oral |
| compartments: | 1 | |
| dosage: | 60 | mg |
| volume of distribution: | 5.5 | L |
| clearance: | 130 | mL/min |
| other parameters in model implementation | ||
Fenfluramine is an amphetamine derivative previously used as an appetite suppressant for the treatment of obesity. It acts as a serotonin-releasing agent. Due to its association with pulmonary hypertension and heart valve disease, fenfluramine was withdrawn from the market in most countries in the late 1990s. It has been re-approved in some regions for the treatment of Dravet syndrome, a rare form of epilepsy, under the branded name Fintepla.
Pharmacokinetics
Pharmacokinetic parameters estimated for healthy adult volunteers after oral administration; typical therapeutic dose.
References
Mittur, A, et al., & Boyd, B (2024). Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine. Journal of clinical pharmacology 64(7) 887–898. DOI:10.1002/jcph.2431 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38523492
Imbeault, P, et al., & Tremblay, A (2002). Increase in plasma pollutant levels in response to weight loss is associated with the reduction of fasting insulin levels in men but not in women. Metabolism: clinical and experimental 51(4) 482–486. DOI:10.1053/meta.2002.31338 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11912558
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)